Skip to main content

Laia Pinos Tella

Institutions of which they are part

Epidemiology and Public Health
Vall Hebron Institut de Recerca

Laia Pinos Tella

Institutions of which they are part

Epidemiology and Public Health
Vall Hebron Institut de Recerca

Projects

Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de Esclerosis Múltiple

IP: Susana Otero Romero
Collaborators: Juliana Esperalba Esquerra, Mar Tintore Subirana, Laia Pinos Tella, Luciana Midaglia Fernandez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: Instituto de Salud Carlos III
Funding: 105270
Reference: PI19/01606
Duration: 01/01/2020 - 30/06/2024

Ensayo clínico para comparar la inmunogenicidad de una vacuna anti-hepatitis B adyuvada con la de carga antigénica aunmentada en pacientres inmunodeprimidos.

IP: -
Collaborators: Manuel Hernández González, Rosa Lopez Martinez , Lluis Armadans Gil, Alexandre Martínez Marti, Laia Pinos Tella, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Blanca Borras Bermejo, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil, Lluis Armadans Gil
Funding agency: Instituto de Salud Carlos III
Funding: 73205
Reference: PI18/01887
Duration: 01/01/2019 - 30/06/2023

Related news

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

Related professionals

Jordi Selga Marsà

Jordi Selga Marsà

Reconstructive Surgery of the Locomotor System
Read more
Alfons Macaya Ruíz

Alfons Macaya Ruíz

Head of group
Pediatric Neurology
Read more
Anna Server Salvà

Anna Server Salvà

Main researcher
Musculoskeletal Tissue Engineering
Read more
Mª Engracia Perez Mezquina

Mª Engracia Perez Mezquina

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.